CAMBRIDGE, Mass. — March 2, 2026 — Leads & Copy — Akebia Therapeutics, Inc. (Nasdaq: AKBA) granted options to purchase 46,200 shares of its common stock to five newly-hired employees on February 27, 2026.
The options serve as an inducement for the new employees joining the biopharmaceutical company, which focuses on improving the lives of individuals affected by kidney disease.
The exercise price for the options is $1.31 per share, equivalent to the closing price of Akebia’s common stock on the grant date. The options vest over a four-year period, with 25% vesting on the first anniversary of the grant date, and the remaining 75% vesting quarterly thereafter, contingent upon the employee’s continued service with Akebia.
Each stock option has a 10-year term and is subject to Akebia’s inducement award program terms and conditions, as well as a stock option agreement.
Akebia Therapeutics, Inc., founded in 2007 and based in Cambridge, Massachusetts, is dedicated to developing treatments for kidney disease.
Source: Akebia Therapeutics
